These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29342416)

  • 1. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
    Fukase Y; Sato A; Tomata Y; Ochida A; Kono M; Yonemori K; Koga K; Okui T; Yamasaki M; Fujitani Y; Nakagawa H; Koyama R; Nakayama M; Skene R; Sang BC; Hoffman I; Shirai J; Yamamoto S
    Bioorg Med Chem; 2018 Feb; 26(3):721-736. PubMed ID: 29342416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of carbazole carboxamides as novel RORγt inverse agonists.
    Huang Y; Yu M; Sun N; Tang T; Yu F; Song X; Xie Q; Fu W; Shao L; Wang Y
    Eur J Med Chem; 2018 Mar; 148():465-476. PubMed ID: 29477887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
    J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.
    Kummer DA; Cummings MD; Abad M; Barbay J; Castro G; Wolin R; Kreutter KD; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Urbanski M; Venkatesan H; Wang A; Woods C; Xue X; Edwards JP; Fourie AM; Leonard K
    Bioorg Med Chem Lett; 2017 May; 27(9):2047-2057. PubMed ID: 28318945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-indanyl benzamides as potent RORγt inverse agonists.
    Tian J; Sun N; Yu M; Gu X; Xie Q; Shao L; Liu J; Liu L; Wang Y
    Eur J Med Chem; 2019 Apr; 167():37-48. PubMed ID: 30743096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecules targeting RORγt inhibit autoimmune disease by suppressing Th17 cell differentiation.
    Tan J; Liu H; Huang M; Li N; Tang S; Meng J; Tang S; Zhou H; Kijlstra A; Yang P; Hou S
    Cell Death Dis; 2020 Aug; 11(8):697. PubMed ID: 32829384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
    Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
    Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
    Gege C; Schlüter T; Hoffmann T
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5265-7. PubMed ID: 25305688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.
    Guendisch U; Weiss J; Ecoeur F; Riker JC; Kaupmann K; Kallen J; Hintermann S; Orain D; Dawson J; Billich A; Guntermann C
    PLoS One; 2017; 12(11):e0188391. PubMed ID: 29155882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003.
    Sasaki Y; Odan M; Yamamoto S; Kida S; Ueyama A; Shimizu M; Haruna T; Watanabe A; Okuno T
    Bioorg Med Chem Lett; 2018 Dec; 28(22):3549-3553. PubMed ID: 30301676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists.
    Wang Y; Yang T; Liu Q; Ma Y; Yang L; Zhou L; Xiang Z; Cheng Z; Lu S; Orband-Miller LA; Zhang W; Wu Q; Zhang K; Li Y; Xiang JN; Elliott JD; Leung S; Ren F; Lin X
    Bioorg Med Chem; 2015 Sep; 23(17):5293-302. PubMed ID: 26277758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives.
    Kono M; Oda T; Tawada M; Imada T; Banno Y; Taya N; Kawamoto T; Tokuhara H; Tomata Y; Ishii N; Ochida A; Fukase Y; Yukawa T; Fukumoto S; Watanabe H; Uga K; Shibata A; Nakagawa H; Shirasaki M; Fujitani Y; Yamasaki M; Shirai J; Yamamoto S
    Bioorg Med Chem; 2018 Jan; 26(2):470-482. PubMed ID: 29258712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.
    Narjes F; Xue Y; von Berg S; Malmberg J; Llinas A; Olsson RI; Jirholt J; Grindebacke H; Leffler A; Hossain N; Lepistö M; Thunberg L; Leek H; Aagaard A; McPheat J; Hansson EL; Bäck E; Tångefjord S; Chen R; Xiong Y; Hongbin G; Hansson TG
    J Med Chem; 2018 Sep; 61(17):7796-7813. PubMed ID: 30095900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Biological Evaluation of Retinoic Acid-Related Orphan Receptor γt (RORγt) Agonist Structure-Based Functionality Switching Approach from In House RORγt Inverse Agonist to RORγt Agonist.
    Yukawa T; Nara Y; Kono M; Sato A; Oda T; Takagi T; Sato T; Banno Y; Taya N; Imada T; Shiokawa Z; Negoro N; Kawamoto T; Koyama R; Uchiyama N; Skene R; Hoffman I; Chen CH; Sang B; Snell G; Katsuyama R; Yamamoto S; Shirai J
    J Med Chem; 2019 Feb; 62(3):1167-1179. PubMed ID: 30652849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of orally efficacious RORγt inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds.
    Shirai J; Tomata Y; Kono M; Ochida A; Fukase Y; Sato A; Masada S; Kawamoto T; Yonemori K; Koyama R; Nakagawa H; Nakayama M; Uga K; Shibata A; Koga K; Okui T; Shirasaki M; Skene R; Sang B; Hoffman I; Lane W; Fujitani Y; Yamasaki M; Yamamoto S
    Bioorg Med Chem; 2018 Jan; 26(2):483-500. PubMed ID: 29262987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Design and Synthesis of Fluorene Derivatives as Novel RORγt Inverse Agonists.
    Gabr MT; Abdel-Raziq MS
    Chem Biodivers; 2018 Sep; 15(9):e1800244. PubMed ID: 29935095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.
    Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA
    J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
    Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
    J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis.
    Xue X; Soroosh P; De Leon-Tabaldo A; Luna-Roman R; Sablad M; Rozenkrants N; Yu J; Castro G; Banie H; Fung-Leung WP; Santamaria-Babi L; Schlueter T; Albers M; Leonard K; Budelsky AL; Fourie AM
    Sci Rep; 2016 Dec; 6():37977. PubMed ID: 27905482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of RORγt activity and Th17 differentiation by a set of novel compounds.
    Ding Q; Zhao M; Bai C; Yu B; Huang Z
    BMC Immunol; 2015 May; 16():32. PubMed ID: 26021566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.